Skip to content
value.today
OvaScience, Inc. logo

OvaScience, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2011
Total raised
$77 M
3 rounds on record
Latest round
$35 M
Mar 2013
First round on record
Mar 2012
Today
Went public
See the company page

OvaScience, Inc. is listed today as Tempest Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of OvaScience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$8 MPrivate placement after listing$2 to $10 million

OvaScience, Inc.: Private sale, Sep 2026

Investors in this round

1 investor had bought by the notice of Oct 14, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: Pre-funded warrants and Series C and Series D Common Stock Purchase Warrants, including underlying shares of common stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$225,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Constance Ames · Executive Officer · Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
  • Matthew Angel · Executive Officer, Director · President and Chief Executive Officer
  • John David Yee · Director
  • John Wilbert Frederick · Director
  • Nancy Freda-Smith · Director
  • William Drake Richey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Includes a cash placement fee equal to 7.0% of the gross proceeds of the offering, reimbursement of $50,000 legal fees and warrants, exercisable upon stockholder approval, to purchase 217,391 common stock at an exercise price of $1.0063 per share.”
  • On the amounts: “Offering of 3,105,591 pre-funded warrants and accompanying 3,105,591 Series C and 3,105,591 Series D warrants, including the common stock underlying such warrants at combined exercise price of $0.804. Total offering amount excludes PA warrants (Item 15).”

Signed by Matthew Angel, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 14, 2026. Read the notice at the SEC.

optionsSEC
May 2026$4 MPrivate placement after listing$2 to $10 million

OvaScience, Inc.: Private sale, May 2026

Investors in this round

1 investor had bought by the notice of Jun 23, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock Purchase Warrant, including underlying shares of common stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin Trojanowski · Executive Officer · Vice President, Finance, Principal Financial Officer and Corporate Secretary
  • Matthew Angel · Executive Officer, Director · President and Chief Executive Officer
  • John David Yee · Director
  • William Drake Richey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering amount for common stock purchase warrant does not include proceeds of $2028276 for warrant exercise. (amounts rounded)”

Signed by Matthew Angel, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 23, 2026. Read the notice at the SEC.

equity, optionsSEC
Mar 2026$2 MPrivate placement after listing$2 to $10 million

OvaScience, Inc.: Private sale, Mar 2026

Investors in this round

3 investors had bought by the notice of Apr 3, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$105,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Angel · Executive Officer, Director
  • Nicholas Maestas · Executive Officer
  • Christine Pellizzari · Director
  • Michael Raab · Director
  • Ronit Simantov · Director
  • Stephen Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Angel, President and CEO. Source: SEC Form D, newest notice filed Apr 3, 2026. Read the notice at the SEC.

equity, optionsSEC
Apr 2022$15 MPrivate placement after listing$10 to $50 million

OvaScience, Inc.: Private sale, Apr 2022

Investors in this round

2 investors had bought by the notice of May 11, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen R. Brady · Executive Officer, Director
  • Thomas W. Dubensky · Executive Officer, Director
  • Christine W. Pellizzari · Director
  • Geoffrey W. Nichol · Director
  • Michael W. Raab · Director
  • Ronit W. Simantov · Director
  • Thomas W. Woiwode · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen R. Brady, Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2022. Read the notice at the SEC.

equity, optionsSEC
Mar 2013$35 MNo. 3$10 to $50 million

OvaScience, Inc.: Raise no. 3, Mar 2013

Investors in this round

31 investors had bought by the notice of Mar 28, 2013: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,099,995
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alison A. Lawton · Executive Officer
  • Christopher A. Bleck · Executive Officer
  • Michelle Dipp · Executive Officer, Director
  • Scott A. Chappel · Executive Officer
  • Christoph A. Westphal · Director
  • Harald A. Stock · Director
  • Jeff A. Capello · Director
  • Jonathan A. Tilly · Director
  • Richard A. Aldrich · Director
  • Stephen A. Kraus · Director
  • Thomas A. Malley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states
  • Wedbush Securities Inc. (CRD 877) · Los Angeles, CaliforniaSold in all US states
  • Leerink Swann LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • Ladenburg Thalman & Co. Inc. (CRD 505) · Miami, FloridaSold in all US states
  • Oppenheimer & Co., Inc. (CRD 249) · New York, New YorkSold in all US states

Signed by Michelle Dipp, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 28, 2013. Read the notice at the SEC.

equitySEC
Jun 2012$5 MNo. 2$2 to $10 million

OvaScience, Inc.: Raise no. 2, Jun 2012

Investors in this round

253 investors had bought by the notice of Aug 14, 2012: 253 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$296,193
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher A. Bleck · Executive Officer
  • Michelle Dipp · Executive Officer, Director
  • Scott A. Chappel · Executive Officer
  • Christoph A. Westphal · Director
  • Jeff A. Capello · Director
  • John A. Simon · Director
  • Jonathan A. Tilly · Director
  • Richard A. Aldrich · Director
  • Stephen A. Kraus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Swann LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • Livingston Securities, LLC (CRD 147364) · New York, New YorkSold in AL, AR, AZ, CA, CT, DE, KY, MA, MD, MI, MS, NC, NH, NJ, NM, NY, OH, OR, PA, RI, TN, VA, WA, WY
  • Oppenheimer & Co., Inc. (CRD 249) · New York, New YorkSold in all US states
  • ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states
  • Newbridge Securities Corporation (CRD 104065) · Fort Lauderdale, FloridaSold in all US states

Signed by Michelle Dipp, President and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Aug 14, 2012. Read the notice at the SEC.

equitySEC
Mar 2012$37 MNo. 1$10 to $50 million

OvaScience, Inc.: Raise no. 1, Mar 2012

Investors in this round

19 investors had bought by the notice of Apr 9, 2012: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for OvaScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $37 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher A. Bleck · Executive Officer
  • Michael A. Flanagan · Executive Officer
  • Michelle Dipp · Executive Officer, Director
  • Scott A. Chappel · Executive Officer
  • Christoph A. Westphal · Director
  • Jeff A. Capello · Director
  • Jonathan A. Tilly · Director
  • Richard A. Aldrich · Director
  • Stephen A. Kraus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michelle Dipp, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 9, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OvaScience, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

That is all the official record says: OvaScience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of OvaScience, Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in OvaScience, Inc.
InvestorKindAmountRoundRoleSource
Bessemer Venture Partners VII Institutional L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Bessemer Venture Partners VII L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
BVP VII Special Opportunity Fund LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Deer Management Co. LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Deer VII & Co. L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Deer VII & Co. Ltd.Companynot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
GC Entrepreneurs Fund V, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
General Catalyst GP V, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
General Catalyst Group V LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
General Catalyst Partners V, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Longwood Fund, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 253 investors.

Largest shareholders today

Institutions holding Tempest Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OvaScience, Inc.
NameRoleNamed in
Constance AmesChief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate SecretaryOct 2026
Justin TrojanowskiVice President, Finance, Principal Financial Officer and Corporate SecretaryJun 2026
Matthew AngelPresident and Chief Executive OfficerJun 2026
Nicholas MaestasExecutive officerApr 2026
Stephen R. BradyExecutive officerMay 2022
Thomas W. DubenskyExecutive officerMay 2022
Alison A. LawtonExecutive officerMar 2013
Christopher A. BleckExecutive officerMar 2013
Michelle DippExecutive officerMar 2013
Scott A. ChappelExecutive officerMar 2013
Michael A. FlanaganExecutive officerApr 2012
John Wilbert FrederickDirectorOct 2026
Nancy Freda-SmithDirectorOct 2026
John David YeeDirectorJun 2026
Matthew AngelPresident and Chief Executive OfficerJun 2026
William Drake RicheyDirectorJun 2026
Christine PellizzariDirectorApr 2026
Michael RaabDirectorApr 2026
Ronit SimantovDirectorApr 2026
Stephen BradyDirectorApr 2026
Christine W. PellizzariDirectorMay 2022
Geoffrey W. NicholDirectorMay 2022
Michael W. RaabDirectorMay 2022
Ronit W. SimantovDirectorMay 2022
Stephen R. BradyDirectorMay 2022
Thomas W. DubenskyDirectorMay 2022
Thomas W. WoiwodeDirectorMay 2022
Christoph A. WestphalDirectorMar 2013
Harald A. StockDirectorMar 2013
Jeff A. CapelloDirectorMar 2013
Jonathan A. TillyDirectorMar 2013
Michelle DippDirectorMar 2013
Richard A. AldrichDirectorMar 2013
Stephen A. KrausDirectorMar 2013
Thomas A. MalleyDirectorMar 2013
John A. SimonDirectorAug 2012

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.